Filter byLast updatedSelectAfterBeforeFrom - ToDateEnd DateCategoryHumanCorporateTopicCOVID-19MedicinesAdvanced therapiesAntimicrobial resistanceBiologicalsBiosimilarsBrexitCareersClinical trialsCompassionate useCompliance and inspectionsCorporateData on medicinesEarly accessFeesGeneric and hybrid medicinesGovernanceInnovationMaximum residue limitMedication errorMedicines for use outside the EUMedicine shortagesMpoxPaediatricsParallel distributionPharmacovigilanceProcurementProduct informationQuality of medicinesRare diseasesReferralsRegulatory and procedural guidanceResearch and developmentScientific adviceScientific guidelinesSMEVaccinesVeterinary limited marketsDiseases areaDiabetesViral diseasesCancerCardiovascular diseasesHIV and AIDSImmune-system diseasesNeurodegenerative diseasesTreatment of human immunodeficiency virus type 1 (HIV-1) infectionResponsible bodyCHMPManagement BoardPDCOPRACCATCMDhCOMPCVMPHMPCPatient safetyYesFiltersResults (5) XevudySort byLast update date (new to old)Last update date (old to new)A-ZZ-AETF warns that monoclonal antibodies may not be effective against emerging strains of SARS-CoV-29 December 2022NewsHumanCOVID-19MedicinesEMA Management Board: highlights of December 2021 meeting17 December 2021NewsCorporateMeeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 December 202117 December 2021NewsHumanCOVID-19MedicinesCOVID-19: EMA recommends authorisation of antibody medicine Xevudy16 December 2021NewsHumanCOVID-19MedicinesEMA receives application for marketing authorisation for Xevudy (sotrovimab) for treating patients with COVID-1918 November 2021NewsHumanCOVID-19Medicines
ETF warns that monoclonal antibodies may not be effective against emerging strains of SARS-CoV-29 December 2022NewsHumanCOVID-19Medicines
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 December 202117 December 2021NewsHumanCOVID-19Medicines
COVID-19: EMA recommends authorisation of antibody medicine Xevudy16 December 2021NewsHumanCOVID-19Medicines
EMA receives application for marketing authorisation for Xevudy (sotrovimab) for treating patients with COVID-1918 November 2021NewsHumanCOVID-19Medicines